Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations-Reference-Cited by-同舟云学术

Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations

Published:2016-12-28 Issue:2 Volume:21 Page:181-190
ISSN:1472-8222
Container-title:Expert Opinion on Therapeutic Targets
language:en
Short-container-title:Expert Opinion on Therapeutic Targets

Author:

Guignabert Christophe¹²,Bailly Sabine³⁴⁵,Humbert Marc¹²⁶

Affiliation:

1. INSERM UMR_S 999, Le Plessis-Robinson, France

2. Univ. Paris-Sud, Université Paris-Saclay, Kremlin-Bicêtre, France

3. INSERM U1036, Grenoble, France

4. Laboratoire Biologie du Cancer et de l’Infection, Commissariat à l’Énergie Atomique et aux Energies Alternatives, Biosciences and Biotechnology Institute of Grenoble, Grenoble, France

5. Université Grenoble-Alpes, Grenoble, France

6. AP-HP, Service de Pneumologie, Centre de Référence de l’Hypertension Pulmonaire Sévère, DHU Thorax Innovation, Hôpital de Bicêtre, France

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14728222.2017.1275567

Reference143 articles.

1. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

2. Pulmonary Arterial Hypertension in France

3. Management of Pulmonary Arterial Hypertension

4. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era

5. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary Hypertension Induced by Right Pulmonary Artery Occlusion: Hemodynamic Consequences of Bmpr2 Mutation;Journal of the American Heart Association;2024-07-16

2. Idiopathic and connective tissue disease-associated pulmonary arterial hypertension (PAH): Similarities, differences and the role of autoimmunity;Autoimmunity Reviews;2024-04

3. Pulmonary arterial hypertension nanotherapeutics: New pharmacological targets and drug delivery strategies;Journal of Controlled Release;2024-01

4. Pulmonary arterial hypertension drugs can partially restore altered angiogenic capacities in bmpr2‐silenced human lung microvascular endothelial cells;Pulmonary Circulation;2023-10

5. FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells;Cell Communication and Signaling;2023-01-30